Morgan Stanley’s Fidelity Disruptive Medicine ETF FMED Stock Holding History

Morgan Stanley’s Portfolio FMED Stock Details FMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-9	Closed	-$230	–	7888
2024 Q1	$230	Sell	9 -9	-50%	-$222	﹤0.01%	7301
2023 Q4	$436	Buy	+18	New	+$391	﹤0.01%	7293

Other funds holding FMED

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

CPBTD

Central Pacific Bank - Trust Division Honolulu, Hawaii $984M AUM 34.19% 1-Year Est. Return

GEA

Glen Eagle Advisors Kingston, New Jersey $714M AUM 18.87% 1-Year Est. Return

Dunhill Financial London, United Kingdom $424M AUM 16.79% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley's FMED Position: Q2 2024 in Review

Morgan Stanley sold out of Fidelity Disruptive Medicine ETF (FMED) in Q2 2024, closing a stake of 9 shares — an estimated $230 sold.

Morgan Stanley first reported a position in FMED in Q4 2023 and held it in 2 quarters. The position peaked at $436 in Q4 2023. 8 funds tracked by Wall St. Rank hold FMED as of Q2 2024.

Morgan Stanley reported no remaining Fidelity Disruptive Medicine ETF position as of Q2 2024 after selling out during the quarter.
Morgan Stanley sold 9 Fidelity Disruptive Medicine ETF shares in Q2 2024, an estimated $230.
Morgan Stanley first reported a position in Fidelity Disruptive Medicine ETF in Q4 2023 and held it in 2 quarters.
Morgan Stanley's Fidelity Disruptive Medicine ETF position peaked at $436 in Q4 2023.
8 funds tracked by Wall St. Rank held Fidelity Disruptive Medicine ETF as of Q2 2024.

Based on Morgan Stanley's 13F filing for Q2 2024, filed 14 Aug 2024.